Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 26Gynecologic 12Gastrointestinal 12Tumor-Agnostic 7Genitourinary 7Other solid neoplasm 6CNS 3Breast 3Sarcoma 2Other hematologic neoplasm 2Head & Neck 2NET 1Endocrine 1Dermatologic 1

Conditions

Mesothelioma, Malignant 2Solid Tumors 1Patients With Any Advanced Solid Tumors 1Mesothelioma 1Malignant Solid Tumour 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 125Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26Specimen Handling 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × nintedanib × Other solid neoplasm × Clear all
NCT02856425 2026-01-20

PEMBIB

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1 Completed
196 enrolled
Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT02863055 2025-09-19

NEMO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
37 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02568449 2021-12-09

Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
20 enrolled 11 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01907100 2019-03-18

Nintedanib (BIBF 1120) in Mesothelioma

Boehringer Ingelheim

Phase 2/3 Terminated
545 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma

NCT01349296 2016-05-20

BARIS

University of Cologne

Phase 1 Completed
18 enrolled
Other solid neoplasm

Solid Tumors

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Boehringer Ingelheim

Phase 1 Completed
61 enrolled
Other solid neoplasm

Malignant Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡